Thermosome - About the company
Thermosome is a seed company based in Munich (Germany), founded in 2014. It operates as a Developer of targeted tumor therapy combined with immune stimulation for cancer. Thermosome has raised $2.16M in funding from Bayern Kapital and HTGF. The company has 3581 active competitors, including 1186 funded and 803 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of targeted tumor therapy combined with immune stimulation for cancer. The company focuses on a new tumor targeting concept for increased local drug concentrations. This aims to achieve improved clinical treatment efficacy. The company is involved in drug development.
- Website
- www.thermosome.com/
- Email ID
- *****@thermosome.com
Key Metrics
Founded Year
2014
Location
Munich, Germany
Stage
Seed
Total Funding
$2.16M in 2 rounds
Latest Funding Round
Investors
Ranked
1291st among 3581 active competitors
Employee Count
6 as on Sep 30, 2026
Similar Companies
Legal entities associated with Thermosome
Thermosome is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Thermosome Gmbh CIN: D2601_HRB189433 , Germany, Active | Dec 17, 2010 | - | - | |
Thermosome Gmbh CIN: HRB189433 , Germany, Active | Dec 16, 2010 | - | - |
Sign up to download Thermosome's company profile
Thermosome's funding and investors
Thermosome has raised a total funding of $2.16M over 2 rounds. Its first funding round was on Apr 06, 2016. Its latest funding round was a Seed round on Apr 06, 2016 for $*****. 2 investors participated in its latest round. Thermosome has 10 institutional investors and 7 angel investors.
Here is the list of recent funding rounds of Thermosome:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 06, 2016 | 4480525 | Seed | 3574922 | 9319021 | 7819858 | 1032734 |
Apr 06, 2016 | 4424729 | Grant (prize money) | 2367822 | 5146356 | 7595649 |
View details of Thermosome's funding rounds and investors
Thermosome's founders and board of directors
Founder? Claim ProfileThermosome's employee count trend
Thermosome has 6 employees as of Sep 26. Here is Thermosome's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Thermosome's Competitors and alternates
Top competitors of Thermosome include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Thermosome, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th | Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
1291st | Thermosome 2014, Munich (Germany), Seed | Developer of targeted tumor therapy combined with immune stimulation for cancer | $2.16M | 37/100 |
Looking for more details on Thermosome's competitors? Click here to see the top ones
Thermosome's Investments and acquisitions
Thermosome has made no investments or acquisitions yet.
Reports related to Thermosome
Here is the latest report on Thermosome's sector:
News related to Thermosome
•
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue SarcomasGlobeNewswire•Jun 24, 2025•Thermosome
•
Thermosome Receives U.S. Orphan Drug Designation for THE001, Expands Patent EstateBenzinga•May 12, 2025•Thermosome
•
Thermosome Receives US Orphan Drug Designation for Lead CompoundGlobeNewswire•May 12, 2025•Thermosome
•
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001GlobeNewswire•Dec 04, 2024•Thermosome
•
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001GlobeNewswire•Nov 19, 2024•Thermosome
•
Thermosome Appoints Dr. Sabine Hauck as Chief Technical OfficerGlobeNewswire•Jun 11, 2024•Thermosome, Leukocare
•
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001BioSpace•Feb 06, 2024•Thermosome
•
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory BoardGlobeNewswire•Dec 05, 2023•Thermosome, CatalYm
•
•
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001GlobeNewswire•Mar 28, 2023•Thermosome
Are you a Founder ?
FAQs about Thermosome
Explore our recently published companies
- Enlist - Unfunded company
- Parisienne - France based, Unfunded company
- ScaleDriver - Claremont based, 2016 founded, Unfunded company